The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches
Open accessAbstract
Introduction Epithelial circulating tumor cells (CTCs) are detectable in patients with non-small cell lung cancer (NSCLC). However, epithelial to mesenchymal transition, a widely reported prerequisite for metastasis, may lead to an underestimation of CTC number. We compared directly an epithelial marker-dependent (CellSearch) and a marker-independent (isolation by size of epithelial tumor cells [ISET]) technology platform for the ability to identify CTCs. Molecular characteristics of CTCs were also explored.Methods Paired peripheral blood samples were collected from 40 chemonäive, stages IIIA to IV NSCLC patients. CTCs were enumerated by Epithelial Cell Adhesion Molecule-based immunomagnetic capture (CellSearch, Veridex) and by filtration (ISET, RareCell Diagnostics). CTCs isolated by filtration were assessed by immunohistochemistry for epithelial marker expression (cytokeratins, Epithelial Cell Adhesion Molecule, epidermal growth factor receptor) and for proliferation status (Ki67).Results CTCs were detected using ISET in 32 of 40 (80%) patients compared with 9 of 40 (23%) patients using CellSearch. A subpopulation of CTCs isolated by ISET did not express epithelial markers. Circulating tumor microemboli (CTM, clusters of ≥ 3 CTCs) were observed in 43% patients using ISET but were undetectable by CellSearch. Up to 62% of single CTCs were positive for the proliferation marker Ki67, whereas cells within CTM were nonproliferative.Conclusions Both technology platforms detected NSCLC CTCs. ISET detected higher numbers of CTCs including epithelial marker negative tumor cells. ISET also isolated CTM and permitted molecular characterization. Combined with our previous CellSearch data confirming CTC number as an independent prognostic biomarker for NSCLC, we propose that this complementary dual technology approach to CTC analysis allows more complete exploration of CTCs in patients with NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While circulating tumor cells (CTCs) are considered a form of liquid biopsy, and we (31) and others (47) have reported on approaches for molecular analysis of CTCs, NSCLC patient CTCs cannot always be reliably identified (44, 48, 49).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,947
Collective cell migration in morphogenesis, regeneration and cancer
Friedl, P., & Gilmour, D. T. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2720 · Cited by 2,804
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Bono, J. S. D., Scher, H. I., Montgomery, B., Parker, C. C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. M. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,189
Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,876
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
Stott, S. L., Hsu, C., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., Rothenberg, S. M., Shah, A. M., Smas, M. E., Korir, G. K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012539107 · Cited by 1,657
Riethdorf, S., Fritsche, H. A., Müller, V., Rau, T., Schindlbeck, C., Rack, B. K., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,365
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,134
Cited by
Sorted by citations
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Progress and prospects of early detection in lung cancer
Knight, S., Crosbie, P. A. J., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 964
Self-citationA microfluidic device for label-free, physical capture of circulating tumor cell clusters
Sarioglu, A. F., Aceto, N., Kojić, N., Collier, M. D., Zeinali, M., Hamza, B. M., Engstrom, A., Zhu, H., Sundaresan, T. K., Miyamoto, D. T., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3404 · Cited by 715
Molecular analysis of circulating tumour cells—biology and biomarkers
Krebs, M., Metcalf, R. L., Carter, L., Brady, G., Blackhall, F. H., & Dive, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.253 · Cited by 638
Self-citationGorges, T. M., Tinhofer, I., Drosch, M., Röse, L., Zollner, T. M., Krahn, T., & von Ahsen, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-178 · Cited by 569
Metadata
- Authors
- Krebs, M. G., Hou, J.-M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., Ward, T. H., Backen, A., Clack, G., Hughes, A., Ranson, M., Blackhall, F. H., & Dive, C.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Cancer Research UK Manchester Institute (GB)
- The Christie NHS Foundation Trust (GB)
- University of Manchester (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Dive, Caroline
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 7
- Issue
- 2
- Pages
- 306-315
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2037607269
- Cited by
- 463
- References
- 40
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 22 · 2023: 23 · 2022: 29 · 2021: 45 · 2020: 39 · 2019: 38 · 2018: 40 · 2017: 47 · 2016: 51 · 2015: 34 · 2014: 27 · 2013: 31 · 2012: 18
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- AstraZeneca
- Cancer Research UK (C147/a12328)
- Academy of Medical Sciences (AMS-SGCL7-Krebs)
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- circulating tumor cells, non-small cell lung cancer, epithelial-mesenchymal transition, CellSearch, circulating tumor microemboli, epithelial markers, Ki-67 proliferation index, EpCAM, cytokeratin, epidermal growth factor receptor, CTC enumeration, prognostic factors
- MeSH terms
- Adenocarcinoma, Aged, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cell Separation, Epithelial Cells, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplastic Cells, Circulating, Prognosis, Prospective Studies, Biomarkers, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
